CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says

AdmilparantNeutral
AI Analysis

Summary

UBS notes that Bristol-Myers protocol changes add risk to Admilparant development while maintaining the drug on track.

Importance:2/10
Sentiment:
0.00
protocol_changeclinical_developmentanalyst_note
Related Companies

Read the original article

Published by yahoo_finance on September 30, 2026 4:34 PM

Read Original